This information was published on 2026-02-19T11:23:33 for IP Right Registration Published.
| Field | Value |
| (210) | 2590322 |
| (220) |
26 Sep 2025
|
| (300) |
US, 01 Apr 2025, 99115705
US, 01 Apr 2025, 99115699 |
| (511) (510) |
Class 5
Pharmaceutical preparations and substances for the treatment of edema, namely, hereditary angioedema; pharmaceutical products and preparations in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders. Class 44 Medical services; medical information services; providing medical and healthcare information for healthcare professionals, caregivers, patients, and providers in the fields of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders via a website; medical consulting services in the field of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders; healthcare services, namely, providing medical and healthcare information in the field of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune lymphoproliferative, and rare diseases and disorders, and collecting data and information on autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders for treatment and diagnostic purposes via an online database; providing medical and healthcare information concerning the screening, diagnosis, and treatment of autosomal dominant, autosomal recessive, genetic, edema, pulmonary, respiratory, ophthalmic, gastrointestinal, skin, autoimmune, lymphoproliferative, and rare diseases and disorders. |
| (540) | DAWNZEER |
| (550) | Word |
| (730) |
Ionis Pharmaceuticals, Inc.
|
| (750) |
Duncan Cotterill Lawyers
|
Find out more about publications on the About page.